ARTICLE | Finance
Biome buddies
Why Enterome spun out microbiome Dx assets into JV with Nestlé
July 15, 2017 2:31 AM UTC
Enterome Bioscience S.A.’s microbiome-based diagnostics have matured to the point of requiring substantial investment to reach the market. A new JV aims to advance the assets without diluting investors, and without stealing focus from the biotech’s therapeutics pipeline.
Enterome and the Nestlé Health Science subsidiary of Nestlé S.A. (SIX:NESN) announced the 50/50 JV July 11. Microbiome Diagnostics Partners (MDP) has rights to Enterome’s diagnostic programs and its microbiome-based diagnostic platform in all therapeutic areas except immuno-oncology. Enterome is not putting any cash into the venture. ...